(Q61443025)

6

Daniel Chandramohan

0 references

Issaka Zongo

2

Issaka Zongo

0 references

Jean-Bosco Ouedraogo

12

Jean-Bosco Ouédraogo

0 references

François Nosten

8

François Nosten

0 references

Brian Greenwood

9

Brian Greenwood

0 references

author name string

Palang Chotsiri

1

0 references

Yves Daniel Compaore

4

0 references

Anyirékun Fabrice Somé

5

0 references

Warunee Hanpithakpong

7

0 references

Philip J Rosenthal

10

0 references

Nicholas J White

11

0 references

Joel Tarning

Creative Commons Attribution 4.0 International

13

0 references

language of work or name

English

0 references

publication date

29 January 2019

0 references

published in

Nature Communications

0 references

volume

10

0 references

issue

1

0 references

page(s)

480

0 references

copyright license

start time

29 January 2019

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1038/s41467-019-08297-9

0 references

cites work

Intermittent preventive treatment against malaria: an update

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

A randomised trial to compare the safety, tolerability and efficacy of three drug combinations for intermittent preventive treatment in children

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Randomized trial of piperaquine with sulfadoxine-pyrimethamine or dihydroartemisinin for malaria intermittent preventive treatment in children

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Effect of coadministered fat on the tolerability, safety, and pharmacokinetic properties of dihydroartemisinin-piperaquine in Papua New Guinean children with uncomplicated malaria.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

In vitro metabolism of piperaquine is primarily mediated by CYP3A4.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Characterization of human urinary metabolites of the antimalarial piperaquine

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Effects of a high-fat meal on the relative oral bioavailability of piperaquine

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Effect of food on the pharmacokinetics of piperaquine and dihydroartemisinin

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

A small amount of fat does not affect piperaquine exposure in patients with malaria

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Population pharmacokinetic assessment of the effect of food on piperaquine bioavailability in patients with uncomplicated malaria

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Variable piperaquine exposure significantly impacts protective efficacy of monthly dihydroartemisinin-piperaquine for the prevention of malaria in Ugandan children

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Characterization of an in vivo concentration-effect relationship for piperaquine in malaria chemoprevention

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Impact of intermittent preventive treatment with dihydroartemisinin-piperaquine on malaria in Ugandan schoolchildren: a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Population Pharmacokinetics and Antimalarial Pharmacodynamics of Piperaquine in Patients With Plasmodium vivax Malaria in Thailand

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Correction: The Effect of Dosing Regimens on the Antimalarial Efficacy of Dihydroartemisinin-Piperaquine: A Pooled Analysis of Individual Patient Data

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in Cambodian children and adults with uncomplicated falciparum malaria

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Increased risk of early vomiting among infants and young children treated with dihydroartemisinin-piperaquine compared with artemether-lumefantrine for uncomplicated malaria

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Comparison of plasma, venous and capillary blood levels of piperaquine in patients with uncomplicated falciparum malaria

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Malaria morbidity in high and seasonal malaria transmission area of Burkina Faso

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Population dynamics of untreated Plasmodium falciparum malaria within the adult human host during the expansion phase of the infection

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Malaria parasite clearance

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

The assessment of antimalarial drug efficacy

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Assessment of the pharmacodynamic properties of antimalarial drugs in vivo

2 references

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

PubMed

https://pubmed.ncbi.nlm.nih.gov/30696903

12 December 2020

inferred from PubMed ID database lookup

Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

In vitro activities of piperaquine and other 4-aminoquinolines against clinical isolates of Plasmodium falciparum in Cameroon

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Impact of antimalarial treatment and chemoprevention on the drug sensitivity of malaria parasites isolated from ugandan children

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Changing antimalarial drug sensitivities in Uganda

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Safety, tolerability, and single- and multiple-dose pharmacokinetics of piperaquine phosphate in healthy subjects.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Humoral responses to plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Benefits of a pharmacology antimalarial reference standard and proficiency testing program provided by the Worldwide Antimalarial Resistance Network (WWARN).

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Perl-speaks-NONMEM (PsN)--a Perl module for NONMEM related programming

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Use of prior information to stabilize a population data analysis

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Mechanistic basis of using body size and maturation to predict clearance in humans

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models

1 reference

https://api.crossref.org/works/10.1038%2FS41467-019-08297-9

7 January 2021

Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of piperaquine in plasma stable isotope labeled internal standard does not always compensate for matrix effects

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/30696903

12 December 2020

inferred from PubMed ID database lookup

The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/30696903

12 December 2020